104224-85-3

Basic information

• Product Name: 2-(1-adamantyl)-4-bromo-1-<(tert-butyldimethylsilyl)oxy>benzene
• Synonyms: 2-(1-adamantyl)-4-bromo-1-<(tert-butyldimethylsilyl)oxy>benzene
• CAS NO: 104224-85-3
• Molecular Weight: 421.493
• Mol File: 104224-85-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-(1-adamantyl)-4-bromo-1-<(tert-butyldimethylsilyl)oxy>benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-adamantyl)-4-bromo-1-<(tert-butyldimethylsilyl)oxy>benzene(104224-85-3)
• EPA Substance Registry System: 2-(1-adamantyl)-4-bromo-1-<(tert-butyldimethylsilyl)oxy>benzene(104224-85-3)

Safety Data

• Hazardous Substances Data: 104224-85-3(Hazardous Substances Data)

Upstream product

• 69739-34-0 t-butyldimethylsiyl triflate 
• 104224-68-2 2-(1-adamantyl)-4-bromophenol 
• 768-95-6 1-adamanthanol 
• 106-41-2 4-bromo-phenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 496858-96-9 (3-(adamantan-1-yl)-4'-vinylbiphenyl-4-oxy)tert-butyldimethylsilane 
• 459423-31-5 3-adamantan-1-yl-4-t-butyldimethylsilanyloxyphenyl boronic acid 
• 107430-94-4 3-(1-adamantyl)-4-<(tert-butyldimethylsilyl)oxy>benzenecarboxaldehyde 
• 915412-02-1 [3-adamantan-1-yl-4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pyridin-3-yl-methanol 
• 915412-04-3 [3-adamantan-1-yl-4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pyridin-3-yl-methanone 
• 862650-93-9 ethyl Z-2-fluoro-3-[3'-(adamantan-1-yl)-4'-tert-butylsilyloxybiphenyl-4-yl]acrylate 
• 862650-92-8 ethyl E-2-fluoro-3-[3'-(adamantan-1-yl)-4'-tert-butylsilyloxybiphenyl-4-yl]acrylate 
• 146966-12-3 3'-(adamantan-1-yl)-4'-tert-butyldimethylsilyloxybiphenyl-4-carboxylic acid 
• 862651-03-4 methyl E-3-[3'-(adamantan-1-yl)-4'-(tert-butyldimethylsilyloxy)-2-formylbiphenyl-4-yl]acrylate 
• 146966-06-5 benzyl 6-<3-(1-adamantyl)-4-<<(trifluoromethyl)sulfonyl>oxy>phenyl>-2-naphthoate 
• 146965-86-8 benzyl 6-<3-(1-adamantyl)-4-(2,3-dihydroxypropyl)phenyl>-2-naphthoate 
• 146965-82-4 benzyl 6-<3-(1-adamantyl)-4-(3-hydroxypropyl)phenyl>-2-naphthoate 
• 146965-80-2 benzyl 6-<3-(1-adamantyl)-4-(1,2-dihydroxyethyl)phenyl>-2-naphthoate 
• 146965-55-1 methyl 6-<3-(1-adamantyl)-4-(benzyloxycarbonyl)phenyl>-2-naphthoate 

Relevant articles and documents

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.

Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis

The present invention relates to the use of at least one RAR receptor agonist ligand, particularly 6-[3-(adamantan-1-yl)-4-(prop-2-ynyloxy)phenyl]naphthalene-2-carboxylic acid or 5-[(E)-3-oxo-3-(5,5,8,8-tetrahydronaphthalene-2-yl)propenyl]thiophene-2-carb